Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948649 · ClinicalTrials.gov registry record · Phase 4
Effects of Chantix on Relapse Prevention for Smoking Cessation
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
NCT00948649: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT00948649 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948649, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
Study Summary
The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.
Interventions
- DRUG Placebo
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948649
The ClinicalTrials.gov registry entry for NCT00948649 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00948649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00948649 about?
NCT00948649 is a clinical study titled "Effects of Chantix on Relapse Prevention for Smoking Cessation". The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.
What is the current status of trial NCT00948649?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2006-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00948649?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00948649?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.